Shanghai MicroPort MedBot Expands Global Reach with Surgical Robot Innovations

An update from Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) is now available.

Shanghai MicroPort MedBot has announced that its cumulative order volume for core products has surpassed 130 units, with the Toumai Laparoscopic Surgical Robot receiving over 70 commercial orders globally. The company has achieved significant milestones in remote surgery, including the first robot-assisted remote surgeries in Europe, showcasing its advanced technology systems. These developments highlight the company’s growing recognition and potential impact in the global surgical robotics market.

The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H

Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology industry, focusing on the development and commercialization of surgical robots. Its primary products include laparoscopic, orthopedic, and vascular interventional surgical robots, with a significant market focus on expanding clinical applications and global registrations.

Average Trading Volume: 8,395,441

Technical Sentiment Signal: Buy

Current Market Cap: HK$17.55B

For detailed information about 2252 stock, go to TipRanks’ Stock Analysis page.